ISRG vs MBOT

Intuitive Surgical (ISRG) remains an undisputed market leader in robotic-assisted surgery, leveraging a formidable installed base, extensive IP, and a deeply embedded recurring revenue stream. Its vision for expanding procedure indications, global reach, and continuous platform innovation supports a strong, durable growth trajectory. However, despite its operational excellence and recent market ca...

Microbot Medical remains an intriguing high-risk, high-reward play in the rapidly expanding robotic endovascular surgery market, buoyed by its FDA-cleared LIBERTY system and proprietary technology. While the previous $15 million public offering temporarily mitigated immediate financial fragility, providing 7-8 months of runway as of late January 2026, approximately 53 days have passed. Assuming a ...